IsoRay Shares Up 20% Amid Positive Brain Cancer Treatment Results

Shares of IsoRay, Inc. ISR are up sharply on Monday amid a positive report of its Cesium-131 therapy.

The company announced that its Cesium-131 therapy stopped brain cancers from recurring in treated locations where previous conventional treatments failed.

From the report:

“According to Dr. Dardis’ presentation, the patients who were treated with the new approach using Cesium-131 fared better than they had using earlier, conventional treatment. In fact, 26 of the 27 patients (96%) had not experienced a recurrence of the treated cancer within the treated bed during the follow-up period.”

Shares of IsoRay were up 21 percent at $1.96.